I thank Ranking Member Walden for yielding, and I commend him for his efforts to limit drug prices and continue innovation. I have a concern about the increased costs that both H.R. 3 and H.R. 19, as well as Senate proposals, could have on small manufacturers through the part D redesign. These small manufacturers often serve the Low-Income Subsidy population that are our most vulnerable, and it would disproportionately affect their access to lifesaving and life-changing medications, such as drugs for mental illness and addiction. H.R. 3 is catastrophic to this population. Madam Chair, I ask to enter into a colloquy with the gentleman from Oregon and seek his commitment to ensure small manufacturers and the LIS population are not inadvertently penalized as this process moves forward of our alternative.
Share
More from Steve Stivers
I claim time in opposition, although I am not opposed to the amendment. The Acting CHAIR. Without objection, the gentleman from Ohio is recognized for 5 minutes. There was no objection.
On Monday, the Rules Committee met and reported a rule for H.R. 5053, the Preventing IRS Abuse and Protecting Free Speech Act, and H.R. 5293, the fiscal year 2017 Department of Defense Appropriations Act. House Resolution 778 provides a…
I thank the gentleman from Tennessee (Mr. David P. Roe) for yielding time. This bill is, indeed, a blending of a bill that Governor DeSantis had in the last Congress and a bill we had in the last Congress, and we now have 321 cosponsors on…
I want to thank the gentleman from Illinois for yielding me time. Mr. Speaker, I rise today to support H.R. 6311, and more specifically, I rise to support bipartisan language to make flexible spending accounts flexible. While 44 percent of…





